Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Rightangled are a CQC registered healthcare provider specialising in genetic testing and is backed by the NHS England. They have designed and filed a patent for their Cardiac genetic test and are now seeking to expand their testing and telemedicine service into new markets and new tests.
days to go:
Expired
investment:
£433,290
Rightangled is a DNA testing company backed by NHS that delivers services to consumers and medical/fitness specialists. The company is a full CQC healthcare provider license that has achieved registration with Bupa, a leading medical insurance company. The company is now planning to move into AI with a solid database. Rightangled has received excellent customer reviews with 5* on Google and 4.5* on Trustpilot. With the proceeds, the company will seek to launch its application, create a strong AI central system, and grow into new markets (US& UAE).
days to go:
Expired
investment:
£311,690
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.
days to go:
Expired
investment:
£270,543
Aerobit is a smart inhaler, a tool for tracking medication use that records each time inhalers are taken and comes in a variety of cool toy designs. Built in sensors can even tell if the inhaler has been shaken correctly.
days to go:
Expired
investment:
£116,960
United Medicine have created a platform where experience, knowledge and opinion of their medical users is used to provide a global consensus and allows the good evidence to be separated from the bad.
days to go:
Expired
investment:
£152,000
The Studio enable members to achieve results through sustainable, structured training. The Studio offer a whole range of sessions such as group classes, one-to-one personal training, spinning and yoga.
days to go:
Expired
investment:
£30,564
Actve is on a mission to build a platform that caters to the new wave of instructors, social media influencers and athletes becoming online content creators. The company aspires to help creators earn an income and build a subscription business. Actve asserts that it caters to a variety of creator needs allowing them to live-stream their workouts, offer guided programs to customers, or use Actve's software to manage their clients. The company aims to become a contender in the digital fitness market that is projected to be worth £21 billion by 2022. It aims to launch its platform in September 2021. Actve will use the investment to develop its platform, hire key staff, build its user base, and work towards becoming an industry champion for fitness creators.
days to go:
Expired
investment:
£166,670
